Pharmaceutical company Alapis announced on Wednesday the signing of a Memorandum of Understanding with CSPC Pharmaceutical Group, one of China΄s leading pharmaceutical companies.
Pursuant to the MoU, Alapis together with CSPC will explore avenues of collaboration in the fields of:
(i) Sourcing of raw materials, such as APIs, for the production of Alapis΄s own pharmaceuticals products;
(ii) Utilise Alapis’s R&D expertise and infrastructure to co-develop new product formulations as well as to register and commercialize existing CSPC products into Greece and other markets where the Company is present;
(iii) Joint Production of pharmaceutical products and
(iv) Exchange of relevant technology and know-how.
Alapis΄s CEO, Stelios Kibaridis, made the following statement regarding the above business developments:
"As China is fast becoming a leading force in the global pharmaceutical industry, we are pleased to have entered into this business agreement with one of China΄s leading industry participants. Our respective operational management teams will continue working closely together to pursue value-enhancing opportunities involving the exchange of know-how and expertise.
We are excited and privileged with the fact that CSPC has identified and chosen Alapis as its credible partner to assist in the promotion of its interests in South East Europe, a process which in the near future will hopefully yield positive and tangible benefits to all parties involved."
Pursuant to the MoU, Alapis together with CSPC will explore avenues of collaboration in the fields of:
(i) Sourcing of raw materials, such as APIs, for the production of Alapis΄s own pharmaceuticals products;
(ii) Utilise Alapis’s R&D expertise and infrastructure to co-develop new product formulations as well as to register and commercialize existing CSPC products into Greece and other markets where the Company is present;
(iii) Joint Production of pharmaceutical products and
(iv) Exchange of relevant technology and know-how.
Alapis΄s CEO, Stelios Kibaridis, made the following statement regarding the above business developments:
"As China is fast becoming a leading force in the global pharmaceutical industry, we are pleased to have entered into this business agreement with one of China΄s leading industry participants. Our respective operational management teams will continue working closely together to pursue value-enhancing opportunities involving the exchange of know-how and expertise.
We are excited and privileged with the fact that CSPC has identified and chosen Alapis as its credible partner to assist in the promotion of its interests in South East Europe, a process which in the near future will hopefully yield positive and tangible benefits to all parties involved."
